Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol.

Evaluation of ex vivo drug combination optimization platform in recurrent high grade astrocytic glioma: An interventional, non-randomized, open-label trial protocol.

<h4>Introduction</h4>High grade astrocytic glioma (HGG) is a lethal solid malignancy with high recurrence rates and limited survival. While several cytotoxic agents have demonstrated efficacy against HGG, drug sensitivity testing platforms to aid in therapy selection are lacking. Patient...

Full description

Bibliographic Details
Main Authors: Tan Boon Toh, Dexter Kai Hao Thng, Nagarjun Bolem, Balamurugan A Vellayappan, Bryce Wei Quan Tan, Yating Shen, Sou Yen Soon, Yvonne Li En Ang, Nivedh Dinesh, Kejia Teo, Vincent Diong Weng Nga, Shiong Wen Low, Pek Lan Khong, Edward Kai-Hua Chow, Dean Ho, Tseng Tsai Yeo, Andrea Li Ann Wong
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2024-01-01
Series:PLoS ONE
Online Access:https://doi.org/10.1371/journal.pone.0307818

Internet

https://doi.org/10.1371/journal.pone.0307818

Similar Items